Call for Abstract
Scientific Program
-
University of Montreal, Canada
University of Washington, USA
Tanzania Vaccine Institute, Tanzania
Alexandria University, Egypt
Lanzhou Veterinary Research Institute, China
Sassari University School of Medicine, Italy
The University of Melbourne, Australia
Technical University of Braunschweig, Germany
Tsukuba Primate Research Center, Japan
Vaccines and Sera Torlak, Serbia
Emory University, USA
Faculdade de Medicina Santo, Brazil
Centro de Ingenieria Genetica y Biotecnologia, Cuba
University of KwaZulu-Natal, Belgium
National Health Research Institute, Taiwan
Korea University, Korea
Center for Genetic Engineering and Biotechnology, Cuba
Indonesian Technical Advisory Committee on Immunization, Indonesia
Walter Reed Army Institute of Research, USA
USAMRIID, USA
Karolinska Institutet, Sweden
Gulu University, Uganda
The Royal Children’s Hospital, Australia
University of Groningen, Netherlands
Central Institute for Research on Goats, India
INSERM, France
University of Sarajevo, Bosnia and Herzegovina
University of British Columbia, Canada
Temple University Center for Biotechnology, USA
UC Davis School of Medicine, USA
The Scripps Research Institute, USA
The University of Tokyo, Japan
Texas Biomedical Research Institute, USA
Flinders University, Australia
The George Washington University, USA
The University of Adelaide, South Australia
University of Michigan Medical School, USA
University of Louisville, USA
National Centre for Biotechnology, Spain
Pontifical Universtity of Salamanca, Spain
Universidade Federal de Goias, Brazil
JJ Strossmayer University, Croatia
Tehran University of Medical Sciences, Iran
Medical University of Vienna, Austria
University of Bedfordshire, UK
University of Oxford, UK
The Tazuke Kofukai Medical Research Institute, Japan
Pasteur Institute of Iran, Iran
Palacky University, Czech Republic
The University of Western Ontario, Canada
Chonbuk National University, South Korea
-
Liquidia Technologies Inc., USA
Profectus BioSciences, Inc., USA
Prokarium Ltd., UK
FluGen Inc., USA
Novartis Vaccines, USA
Merck & Co., Inc., USA
Arbovax Inc., USA
Merck Millipore, Europe
Sanofi Pasteur, USA
UNIVAC llc, Belgium
Bavarian Nordic, Germany
VALNEVA, Austria
Cellular Technology Limited, USA
Celldex Therapeutics, USA
Serum Institute of India, India
Vedantra Pharmaceuticals, USA
Shanghai Zerun Biotechnology Co .,Ltd. China
GenPhar Inc., USA
InnaVirVax, USA
West Pharmaceutical Services, USA
Inovio Pharmaceuticals, USA
VaxInnate Corporation, USA
Vaxart, Inc., USA
Iliad Biotechnologies, Scotland
European Institute of Innovation and Technology, Europe
REIMS, France
International Vaccine Institute, Korea
Micronutrient Initiative, Bangladesh
Slovak Academy of Sciences, Solvakia
5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, will be organized around the theme “Vaccine Research: From Bench to Bedside”
Vaccines Asia Pacific-2015 is comprised of 22 tracks and 121 sessions designed to offer comprehensive sessions that address current issues in Vaccines Asia Pacific-2015.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Tetanus, diphtheria, acellular pertussis vaccine during pregnancy
- Track 1-2Diphtheria and tetanus toxoids usage in pediatrics
- Track 1-3Administration and routes of administration of toxoids
- Track 1-4Innovative toxoid vaccine development
- Track 1-5Maternal immunization
- Track 1-6Others
- Track 3-1Challenges and Innovation
- Track 3-2Planning
- Track 3-3Business Development of Animal Vaccines
- Track 3-4Business Development of Human Vaccines
- Track 3-5Phyto vaccines
- Track 4-1Peptide Based vaccines
- Track 4-2Protein based vaccines
- Track 4-3Others
- Track 5-1Progress and challenges
- Track 5-2Others
- Track 6-1Cancer Therapeutic Vaccines
- Track 6-2Vaccines for Preventive cancer
- Track 6-3Others
- Track 7-1Chickenpox vaccines
- Track 7-2Diphtheria vaccines
- Track 7-3Polio vaccines
- Track 7-4Hib Vaccines
- Track 7-5Hepatitis A vaccines
- Track 7-6Hepatitis B vaccines
- Track 7-7Flu vaccines
- Track 7-8Measles vaccines
- Track 7-9Mumps vaccines
- Track 7-10Pertussis vaccines
- Track 7-11Pneumococcal vaccines
- Track 7-12Rotavirus vaccines
- Track 7-13Rubella vaccines
- Track 7-14Tetanus vaccines
- Track 7-15Others
- Track 8-1Mucosal Vaccines Design
- Track 8-2Mucosal Vaccines Delivery
- Track 8-3Others
- Track 9-1Dendritic cell based vaccines and development
- Track 9-2Recombinent vector based immunization
- Track 9-3DNA Vaccination
- Track 9-4T-cell receptor peptide vaccines
- Track 9-5Targeted bacterial protein identification
- Track 9-6Others
- Track 10-1HIV vaccine
- Track 10-2Ebola vaccine
- Track 10-3Cancer vaccination
- Track 10-4Vaccine for severe acute respiratory syndrome
- Track 10-5Need of vaccination for major diseases
- Track 10-6Others
- Track 11-1Immunization and its side effects in geriatrics
- Track 11-2Vaccine dosing and administration in older adults
- Track 11-3Herpes zoster vaccine
- Track 11-4Pneumococcal polysaccharide vaccine
- Track 11-5Contraindications and precautions during vaccination in geriatrics
- Track 11-6Risk factors in geriatric immunization
- Track 11-7Others
- Track 12-1Recent trends in vaccines development path
- Track 12-2Current technologies using in vaccines discovery
- Track 12-3New vaccines against infectious diseases
- Track 12-4Recent technologies in modifying bacterial genome
- Track 13-1Role of nanotechnology in vaccine delivery
- Track 13-2Hepatitis B virus spread and control
- Track 13-3Recombinant technology usage
- Track 13-4Virus-like particles as vaccines, vectors and adjutants
- Track 13-5Vaccines and its target compositions
- Track 13-6Others
- Track 14-1Safety considerations in vaccination
- Track 14-2Vaccines and vaccination knowledge
- Track 14-3Health care outcomes of different aged people vaccinated
- Track 14-4Safety and efficacy of vaccines
- Track 14-5Vaccines and vaccination- health care improvement.
- Track 14-6Others
- Track 15-1Preclinical stage development and factors affecting
- Track 15-2Clinical stage process
- Track 15-3Vaccines efficacy testing
- Track 15-4Manufacture of the vaccine to Good Manufacturing Practice standards
- Track 15-5Complications and consequences affecting vaccine development
- Track 15-6Others
- Track 16-1Yellow fever: Epidemiology and prevention
- Track 16-2Typhoid fever vaccination
- Track 16-3Advantage of live attenuated vaccines
- Track 16-4Risk factors in unsing live attenuated vaccines
- Track 16-5Tubercular vaccination
- Track 16-6Cancer Therapeutic Vaccination
- Track 16-7Others
- Track 17-1Conjugated vaccine discovery and translation of new vaccine technology
- Track 17-2Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants
- Track 17-3Production of Conjugate Vaccines Using Recombinant DNA Technology
- Track 17-4Manufacturing of Conjugate Vaccines
- Track 17-5Effect of pneumococcal conjugate vaccine on pneumococcal meningitis
- Track 17-6Others
- Track 18-1Designing of adjutvants
- Track 18-2Rationale selection of adjuvants
- Track 18-3Skin delivery techniques
- Track 18-4Adjuvant interactions
- Track 18-5BeneficialAdjuvents
- Track 18-6Others
- Track 19-1Bovine vaccine technology
- Track 19-2Pet vaccines and vaccination
- Track 19-3Animal health outcomes
- Track 19-4Animal diseases and vaccination
- Track 19-5Current status of veterinary vaccines
- Track 19-6Others
- Track 20-1Whooping cough Vaccines in pregnant women
- Track 20-2Immunization before pregnancy
- Track 20-3Immunization during pregnancy
- Track 20-4Consequences of halting vaccination in pregnancy
- Track 20-5Chiropractic vaccination care in women and pregnancy
- Track 20-6Others
- Track 21-1Major discoveries in carbohydrate based vaccines
- Track 21-2Glycomics- Vaccine Discoveries
- Track 21-3Identification, synthesis and evaluation of unique glycan epitopes
- Track 21-4Targeting the surface carbohydrates of infectious agents
- Track 21-5Role of carbohydrate-based vaccines in cancer therapy
- Track 21-6Others
- Track 22-1New approaches to combat bacterial pathogens
- Track 22-2Public health concerns in vaccination
- Track 22-3Contraindications of vaccinations
- Track 22-4Vaccines formulation and technologies used in conjugated vaccines
- Track 22-5Vaccine resistance and need of Next-Gen Conjugate Vaccines
- Track 22-6Others